Literature DB >> 30341603

Differential Scanning Fluorimetry and Hydrogen Deuterium Exchange Mass Spectrometry to Monitor the Conformational Dynamics of NBD1 in Cystic Fibrosis.

Naoto Soya1, Ariel Roldan1, Gergely L Lukacs2,3.   

Abstract

Cystic fibrosis (CF) is one of the most common, lethal autosomal recessive diseases in Caucasians with a life expectancy of 37-47 years. The CF transmembrane conductance regulator (CFTR) is a plasma membrane ion channel, confined to apical membrane of epithelia, and ensures transepithelial water and solute movement across secretory epithelia in several organs. Numerous CF mutations, including the most prevalent deletion of F508 (ΔF508) in the nucleotide binding domain 1 (NBD1) leads to CFTR global misfolding and premature intracellular degradation at the endoplasmic reticulum (ER). To better understand the misfolding mechanism caused by CF-causing point mutations in the NBD1, which is poorly understood, differential scanning fluorimetry (DSF) and hydrogen deuterium exchange coupled with mass spectrometry (HDX-MS) are the choice of techniques. These established methods can measure the conformational dynamics of the NBD1 globally and at peptide resolution level by monitoring backbone amide HDX, respectively, and will be instrumental to evaluate the mechanism of action of CF mutations and folding correctors that rescue CFTR folding defects via stabilizing the mutant NBD1.

Entities:  

Keywords:  Conformational diseases; Cystic fibrosis; Melting temperature; Missense mutation; NBD1; Thermal stability; Unfolding kinetic

Mesh:

Substances:

Year:  2019        PMID: 30341603      PMCID: PMC8311558          DOI: 10.1007/978-1-4939-8820-4_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  22 in total

Review 1.  Hydrogen exchange mass spectrometry for the analysis of protein dynamics.

Authors:  Thomas E Wales; John R Engen
Journal:  Mass Spectrom Rev       Date:  2006 Jan-Feb       Impact factor: 10.946

2.  Minimizing carry-over in an online pepsin digestion system used for the H/D exchange mass spectrometric analysis of an IgG1 monoclonal antibody.

Authors:  Ranajoy Majumdar; Prakash Manikwar; John M Hickey; Jayant Arora; C Russell Middaugh; David B Volkin; David D Weis
Journal:  J Am Soc Mass Spectrom       Date:  2012-09-20       Impact factor: 3.109

3.  Differential scanning fluorimetry measurement of protein stability changes upon binding to glycosaminoglycans: a screening test for binding specificity.

Authors:  Katarzyna A Uniewicz; Alessandro Ori; Ruoyan Xu; Yassir Ahmed; Mark C Wilkinson; David G Fernig; Edwin A Yates
Journal:  Anal Chem       Date:  2010-05-01       Impact factor: 6.986

4.  False EX1 signatures caused by sample carryover during HX MS analyses.

Authors:  Jing Fang; Kasper D Rand; Penny J Beuning; John R Engen
Journal:  Int J Mass Spectrom       Date:  2011-04-30       Impact factor: 1.986

5.  Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator.

Authors:  J Michael Younger; Liling Chen; Hong-Yu Ren; Meredith F N Rosser; Emma L Turnbull; Chun-Yang Fan; Cam Patterson; Douglas M Cyr
Journal:  Cell       Date:  2006-08-11       Impact factor: 41.582

6.  Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry.

Authors:  H A Lewis; C Wang; X Zhao; Y Hamuro; K Conners; M C Kearins; F Lu; J M Sauder; K S Molnar; S J Coales; P C Maloney; W B Guggino; D R Wetmore; P C Weber; J F Hunt
Journal:  J Mol Biol       Date:  2009-11-26       Impact factor: 5.469

7.  Hydrogen exchange-mass spectrometry: optimization of digestion conditions.

Authors:  Lintao Wang; Hai Pan; David L Smith
Journal:  Mol Cell Proteomics       Date:  2002-02       Impact factor: 5.911

8.  Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.

Authors:  Fredrick Van Goor; Haihui Yu; Bill Burton; Beth J Hoffman
Journal:  J Cyst Fibros       Date:  2013-07-23       Impact factor: 5.482

9.  Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy.

Authors:  Justin D Hall; Hong Wang; Laura J Byrnes; Suman Shanker; Kelong Wang; Ivan V Efremov; P Andrew Chong; Julie D Forman-Kay; Ann E Aulabaugh
Journal:  Protein Sci       Date:  2016-01-12       Impact factor: 6.725

10.  From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations.

Authors:  Gudio Veit; Radu G Avramescu; Annette N Chiang; Scott A Houck; Zhiwei Cai; Kathryn W Peters; Jeong S Hong; Harvey B Pollard; William B Guggino; William E Balch; William R Skach; Garry R Cutting; Raymond A Frizzell; David N Sheppard; Douglas M Cyr; Eric J Sorscher; Jeffrey L Brodsky; Gergely L Lukacs
Journal:  Mol Biol Cell       Date:  2016-02-01       Impact factor: 4.138

View more
  2 in total

1.  Nanomechanics combined with HDX reveals allosteric drug binding sites of CFTR NBD1.

Authors:  Rita Padányi; Bianka Farkas; Hedvig Tordai; Bálint Kiss; Helmut Grubmüller; Naoto Soya; Gergely L Lukács; Miklós Kellermayer; Tamás Hegedűs
Journal:  Comput Struct Biotechnol J       Date:  2022-05-23       Impact factor: 6.155

2.  Spatial covariance analysis reveals the residue-by-residue thermodynamic contribution of variation to the CFTR fold.

Authors:  Frédéric Anglès; Chao Wang; William E Balch
Journal:  Commun Biol       Date:  2022-04-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.